Ref to what have circulated in some websites and local newspapers regarding the safety alerts involved in using Avandia (Rosiglitazone), a drug approved for treating type 2 diabetes, the Ministry of Health would like to inform that no evidence of any risk of heart attack or heart related deaths have so far been confirmed. It is, therefore, advised that patients should continue using the drug unless the doctor following a specific case sees otherwise. But MOH at the same time advises that utmost care must be taken in using Avandia for treating diabetic heart and kidney patients. It is also worth mentioning that the American Food and Drug Administration (FDA) has advised after necessary analysis that the medicine must not be recalled from pharmacies. FDA has also advised patients who are taking Avandia that they should not stop using the drug without consulting the doctor following the case.